Takeo Fujii1, Naoki Nishimura2, Kevin Y Urayama3, Hisako Kanai4, Hiromasa Ishimaru5, Junko Kawano6, Osamu Takahashi7, Hideko Yamauchi6, Teruo Yamauchi8. 1. Division of Medical Oncology, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan Division of Pulmonary Medicine, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan. 2. Division of Pulmonary Medicine, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan nina@luke.ac.jp. 3. Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo, Japan Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, Japan. 4. Breast Center/Oncology Center, St. Luke's International Hospital, Tokyo, Japan. 5. Department of Pharmacology, St. Luke's International Hospital, Tokyo, Japan. 6. Department of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan. 7. Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, Japan. 8. Division of Medical Oncology, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. RESULTS: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines. Copyright
BACKGROUND: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. RESULTS: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines. Copyright
Authors: Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland Journal: Oncologist Date: 2019-12-04
Authors: Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland Journal: Oncologist Date: 2019-12-08